Castle Biosciences
(NASDAQ) CSTL
Castle Biosciences Financials at a Glance
Market Cap
$627.83M
Revenue (TTM)
$339.92M
Net Income (TTM)
-$12.83M
EPS (TTM)
-$0.43
P/E Ratio
-48.20
Dividend
$0.00
Beta (Volatility)
1.46 (Average)
Dividend
$0.00
Beta (Volatility)
1.46 (Average)
Price
$20.65
Volume
0
Open
$21.01
Price
$20.65
Volume
0
Open
$21.01
Previous Close
$20.65
Daily Range
$20.56 - $21.15
52-Week Range
$14.59 - $44.28
Estimated Earnings Date
Aug 3, 2026
Dividend
$0.00
Beta (Volatility)
1.46 (Average)
Price
$20.65
Volume
0
Open
$21.01
Previous Close
$20.65
Daily Range
$20.56 - $21.15
52-Week Range
$14.59 - $44.28
Estimated Earnings Date
Aug 3, 2026
CSTL News
CSTL: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Castle Biosciences
Industry
Healthcare Providers and Services
Sector
Health CareEmployees
883
CEO
Derek J. Maetzold
Website
www.castlebiosciences.comHeadquarters
Friendswood, TX 77546, US
CSTL Financials
Key Financial Metrics (TTM)
Gross Margin
77%
Operating Margin
-10%
Net Income Margin
-4%
Return on Equity
-3%
Return on Capital
-7%
Return on Assets
-2%
Earnings Yield
-2.07%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$627.83M
Shares Outstanding
30.33M
Volume
0
Avg. Volume
372.29K
Financials (TTM)
Gross Profit
$273.20M
Operating Income
-$42.81M
EBITDA
$11.34M
Operating Cash Flow
$64.35M
Capital Expenditure
-$36.02M
Free Cash Flow
$28.33M
Cash & ST Invst.
$299.51M
Total Debt
$36.91M
Castle Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$83.68M
-4.9%
Gross Profit
$60.38M
-15.7%
Gross Margin
72.15%
N/A
Market Cap
$627.83M
N/A
Market Cap/Employee
$800.80K
N/A
Employees
784
N/A
Net Income
-$14.52M
+43.8%
EBITDA
-$10.35M
-394.9%
Quarterly Fundamentals
Total Cash
$261.69M
-4.9%
Total Debt
$36.72M
+42.1%
Accounts Receivable
$42.26M
-25.0%
Inventory
$10.46M
+52.7%
Long Term Debt
$33.80M
+45.1%
Short Term Debt
$2.92M
+14.7%
Return on Assets
-2.34%
N/A
Return on Invested Capital
-6.67%
N/A
Free Cash Flow
-$34.58M
-220.9%
Operating Cash Flow
-$22.13M
-266.6%